SEC Form SC 13G/A filed by Exelixis Inc. (Amendment)

2/14/23 12:38:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $EXEL alert in real time by email

SC 13G/A 1 exel13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) EXELIXIS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 30161Q104 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 1,417,152 6. Shared Voting Power* 0 7. Sole Dispositive Power* 6,627,890 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 6,627,890 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 2.1% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: EXELIXIS INC Item 1(b) Address of Issuer's Principal Executive Offices: 1851 HARBOR BAY PARKWAY, ALAMEDA, CALIFORNIA 94502 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 30161Q104 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 14, 2023 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2022

Get the next $EXEL alert in real time by email

Recent Analyst Ratings for

$EXEL

Date	Price Target	Rating	Analyst
2/24/2025	$36.00	Overweight → Equal Weight	Wells Fargo
1/27/2025	$30.00 → $40.00	Equal-Weight → Overweight	Morgan Stanley
1/24/2025		Outperform → Perform	Oppenheimer
12/20/2024	$36.00 → $40.00	Outperform → Market Perform	BMO Capital Markets
12/17/2024	$35.00 → $39.00	Buy → Neutral	BofA Securities
10/16/2024	$30.00 → $34.00	Outperform	RBC Capital Mkts
9/19/2024	$30.00	Neutral	UBS
4/11/2024	$25.00	Overweight → Equal Weight	Barclays

More analyst ratings

SEC Form SC 13G/A filed by Exelixis Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $EXEL

$EXEL Press Releases

Fastest customizable press release news feed in the world

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

$EXEL FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for CABOMETYX issued to EXELIXIS INC

FDA Approval for CABOMETYX issued to EXELIXIS INC

FDA Approval for CABOMETYX issued to EXELIXIS INC

$EXEL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

Johnson David Edward sold $2,602,038 worth of shares (120,409 units at $21.61) and bought $2,602,038 worth of shares (120,409 units at $21.61) (SEC Form 4)

$EXEL Leadership Updates

Live Leadership Updates

ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

$EXEL Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

SEC Form SC 13G filed by Exelixis Inc.

SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

$EXEL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Commercial Haley Patrick J. sold $1,515,091 worth of shares (34,387 units at $44.06), decreasing direct ownership by 8% to 412,072 units (SEC Form 4)

Director Heyman Tomas J. sold $201,254 worth of shares (4,544 units at $44.29), decreasing direct ownership by 12% to 32,470 units (SEC Form 4)

Director Poste George exercised 20,634 shares at a strike of $19.77 and sold $948,958 worth of shares (20,634 units at $45.99) (SEC Form 4)

$EXEL SEC Filings

SEC Form 144 filed by Exelixis Inc.

SEC Form 144 filed by Exelixis Inc.

SEC Form 10-Q filed by Exelixis Inc.

$EXEL Financials

Live finance-specific insights

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

$EXEL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Exelixis downgraded by Wells Fargo with a new price target

Exelixis upgraded by Morgan Stanley with a new price target

Exelixis downgraded by Oppenheimer

Recent Analyst Ratings for
$EXEL

$EXEL
Press Releases

$EXEL
FDA approvals

$EXEL
Insider Purchases

$EXEL
Leadership Updates

$EXEL
Large Ownership Changes

$EXEL
Insider Trading

$EXEL
SEC Filings

$EXEL
Financials

$EXEL
Analyst Ratings